share_log

Insulet | 10-Q: Q3 2024 Earnings Report

Insulet | 10-Q: Q3 2024 Earnings Report

銀休特 | 10-Q：2024財年三季報
美股SEC公告 ·  2024/11/09 02:26

Moomoo AI 已提取核心訊息

Insulet Corporation reported strong financial results for Q3 2024, with total revenue increasing 25.7% to $543.9 million, driven by robust Omnipod sales growth. U.S. Omnipod revenue rose 23.4% to $395.6 million, while International Omnipod revenue jumped 36.1% to $138.0 million. Net income grew 49.3% to $77.5 million, with gross margin improving to 69.3% from 67.8% year-over-year.The company achieved significant operational milestones, including the launch of Omnipod 5 with Dexcom's G7 CGM in the U.S. and expansion of Omnipod 5 availability in European markets. Production began at the new Malaysia manufacturing facility, which is expected to drive higher gross margins over time. The company also received FDA clearance for Omnipod 5 use in type 2 diabetes patients.Looking ahead, Insulet expects continued strong revenue growth driven by Omnipod 5 adoption and international expansion. The company maintains a solid financial position with $902.6 million in cash and cash equivalents. Management anticipates full-year 2024 gross margin to be approximately 69%, supported by higher average selling prices and improved manufacturing efficiencies.
Insulet Corporation reported strong financial results for Q3 2024, with total revenue increasing 25.7% to $543.9 million, driven by robust Omnipod sales growth. U.S. Omnipod revenue rose 23.4% to $395.6 million, while International Omnipod revenue jumped 36.1% to $138.0 million. Net income grew 49.3% to $77.5 million, with gross margin improving to 69.3% from 67.8% year-over-year.The company achieved significant operational milestones, including the launch of Omnipod 5 with Dexcom's G7 CGM in the U.S. and expansion of Omnipod 5 availability in European markets. Production began at the new Malaysia manufacturing facility, which is expected to drive higher gross margins over time. The company also received FDA clearance for Omnipod 5 use in type 2 diabetes patients.Looking ahead, Insulet expects continued strong revenue growth driven by Omnipod 5 adoption and international expansion. The company maintains a solid financial position with $902.6 million in cash and cash equivalents. Management anticipates full-year 2024 gross margin to be approximately 69%, supported by higher average selling prices and improved manufacturing efficiencies.
銀休特公司報告了2024年第三季度強勁的財務業績，總營業收入增加了25.7%，達到54390萬美元，主要受益於Omnipod銷售增長。美國Omnipod營業收入增長了23.4%，達到39560萬美元，而國際Omnipod營業收入猛增36.1%，達到13800萬美元。凈利潤增長了49.3%，達到7750萬美元，毛利率從67.8%提高到69.3%。該公司實現了顯著的運營里程碑，包括在美國推出與德康醫療的G7 CGM兼容的Omnipod 5，並擴大了Omnipod 5在歐洲市場的可用性。新建的馬來西亞製造業工廠已開始生產，預計將隨着時間的推移推動更高的毛利率。該公司還獲得了FDA批准，允許在2型糖尿...展開全部
銀休特公司報告了2024年第三季度強勁的財務業績，總營業收入增加了25.7%，達到54390萬美元，主要受益於Omnipod銷售增長。美國Omnipod營業收入增長了23.4%，達到39560萬美元，而國際Omnipod營業收入猛增36.1%，達到13800萬美元。凈利潤增長了49.3%，達到7750萬美元，毛利率從67.8%提高到69.3%。該公司實現了顯著的運營里程碑，包括在美國推出與德康醫療的G7 CGM兼容的Omnipod 5，並擴大了Omnipod 5在歐洲市場的可用性。新建的馬來西亞製造業工廠已開始生產，預計將隨着時間的推移推動更高的毛利率。該公司還獲得了FDA批准，允許在2型糖尿病患者中使用Omnipod 5。展望未來，銀休特預計Omnipod 5的採納和國際擴展將推動持續強勁的營業收入增長。該公司保持穩健的財務狀況，現金及現金等價物達到90260萬美元。管理層預計2024年全年毛利率將約爲69%，並將受益於更高的平均售價和改善的製造效率。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    艾里德克斯
    IRIX
    -- 0.999
    Helius Medical Technologies
    HSDT
    -- 0.4200
    VolitionRX
    VNRX
    -- 0.550
    HeartSciences
    HSCS
    -- 2.9600
    Outset Medical
    OM
    -- 12.580
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    中概股財報季火熱：驚喜盈利能否延續漲勢？
    1. 哪些行業可能成為本輪財報季的市場焦點？ 2. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點